Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB).

ABSTRACT:

Background

With current treatment options most patients with CNS TB develop severe disability or die. Drug-resistant tuberculous meningitis is nearly uniformly fatal. Novel treatment strategies are needed. Bedaquiline, a potent anti-TB drug, has been reported to be absent from CSF in a single report.

Objectives

To explore the pharmacokinetics of bedaquiline and its M2 metabolite in the CSF of patients with pulmonary TB.

Patients and methods

Individuals with rifampicin-resistant pulmonary TB established on a 24 week course of treatment with bedaquiline underwent a lumbar puncture along with multiple blood sample collections over 24 h for CSF and plasma pharmacokinetic assessment, respectively. To capture the expected low bedaquiline and M2 concentrations (due to high p

SUBMITTER: Upton CM 

PROVIDER: S-EPMC9633714 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature